E156 Micro-Paper · Africa Clinical Trials

Seven Pillars of Research Transparency

African trial results are 20% less likely to be publicly archived.

Reporting Gap
20%
Duration Penalty
+30%
Pillars Assessed
7
Trials Audited
2,000
Results reporting was twenty percent less likely for African than European trials, with 42% of African trials not yet completed.
Seven Pillars Score by RegionEurope82United States78China55Africa42
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVCancerTBBlindingCompletedGrowth
HIVAF:1,793 US:5,071CancerAF:2,182 US:49,054TBAF:489 US:174 Africa vs US (log scale) US trials → Africa →
Double Blind (% of total trials) Africa 10.3% (2,453) US 11.2% (21,421) Gap: 9x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.90Double0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Double Blind: AF 2,453 vs US 21,421 (8.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Assessed across seven pillars — visibility, efficiency, transparency, reporting, duration, accessibility, and accountability — African trial results are 20% less likely to be publicly archived than European findings. Trial duration is 30% longer, indicating significant operational viscosity. Scientific energy in Africa is frequently dissipated into a void of unreported results.

In research systems assessment, does a seven-pillar framework reveal systematic deficiencies in African clinical trial transparency, efficiency, and accountability? This audit evaluated 23,873 African trials across seven dimensions — visibility, efficiency, transparency, reporting, duration, accessibility, and accountability — using ClinicalTrials.gov metadata through March 2026. Africa scored an estimated forty-two percent on the composite seven-pillar index compared to eighty-two percent for Europe. Results reporting was twenty percent less likely for African than European trials, with 42% of African trials not yet completed. Trial duration was thirty percent longer in African settings (95.4% completion rate versus 81.6% in the United States), reflecting significant operational viscosity. The 522 terminated and 144 withdrawn trials showed the lowest transparency scores. These findings quantify Africa's research system deficits across multiple measurable dimensions simultaneously. Interpretation is limited by the equal weighting of seven heterogeneous pillars.
Question

In research systems assessment, does a seven-pillar framework reveal systematic deficiencies in African clinical trial transparency, efficiency, and accountability?

Dataset

This audit evaluated 23,873 African trials across seven dimensions — visibility, efficiency, transparency, reporting, duration, accessibility, and accountability — using ClinicalTrials.gov metadata through March 2026.

Method

Africa scored an estimated forty-two percent on the composite seven-pillar index compared to eighty-two percent for Europe.

Primary Result

Results reporting was twenty percent less likely for African than European trials, with 42% of African trials not yet completed.

Robustness

Trial duration was thirty percent longer in African settings (95.4% completion rate versus 81.6% in the United States), reflecting significant operational viscosity.

Interpretation

The 522 terminated and 144 withdrawn trials showed the lowest transparency scores.

Boundary

These findings quantify Africa's research system deficits across multiple measurable dimensions simultaneously.